- About Us
- Career Center
- Nano-Social Network
- Nano Consulting
- My Account
Tumors are complex collections of cells whose behavior has proven difficult to understand, let alone predict. As a result, oncologists are often surprised by how a particular patient responds to a given course of therapy.
Enter mathematics. Using a sophisticated mathematical model that relates a wide variety of biological variables to disease progression, a research team headed by Vittorio Cristini, Ph.D., and Mauro Ferrari, Ph.D., the University of Texas Health Science Center in Houston, and David B. Agus, M.D., the University of Southern California and the Center for Cancer Nanotechnology Excellence Focused on Therapy Response, has shown that accounting for the shape and physical characteristics of the tumor margin and invasiveness of the tumor accurately predicts how a particular tumor will develop and metastasize. The results of this study appear in the journal Cancer Research.
One of the major findings of this study is that tumor progression is not a random process, but rather one that responds predictably based on well-established biophysical laws, genetic effects, and the microenvironment surrounding a tumor, among other factors. The model predicts that different tumor morphologies—the shapes and structural features of a given tumor—influence a tumor's ability to infiltrate otherwise healthy tissue in a predictable manner. Tumor morphology is determined as part of the standard procedures used to characterize tumors from tissue biopsies.
The researchers note that this model may provide new insights into how a tumor is perturbed by various therapies. If so, this model could prove useful in designing new clinical endpoints in therapeutic trials and ultimately in predicting patient response to a given therapy based on the unique physical characteristics of that patient's disease.
To help meet the goal of reducing the burden of cancer, the National Cancer Institute (NCI), part of the National Institutes of Health, is engaged in efforts to harness the power of nanotechnology to radically change the way we diagnose, treat and prevent cancer.
The NCI Alliance for Nanotechnology in Cancer is a comprehensive, systematized initiative encompassing the public and private sectors, designed to accelerate the application of the best capabilities of nanotechnology to cancer.
Currently, scientists are limited in their ability to turn promising molecular discoveries into benefits for cancer patients. Nanotechnology can provide the technical power and tools that will enable those developing new diagnostics, therapeutics, and preventives to keep pace with today’s explosion in knowledge.
For more information, please click here
National Cancer Institute
Office of Technology & Industrial Relations
ATTN: NCI Alliance for Nanotechnology in Cancer
Building 31, Room 10A49
31 Center Drive , MSC 2580
Bethesda , MD 20892-2580
Copyright © National Cancer InstituteIf you have a comment, please Contact us.
Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.
|Related News Press|
News and information
The NanoWizard® AFM from JPK is applied for interdisciplinary research at the University of South Australia for applications including smart wound healing and how plants can protect themselves from toxins July 26th, 2016
Accurate design of large icosahedral protein nanocages pushes bioengineering boundaries: Scientists used computational methods to build ten large, two-component, co-assembling icosahedral protein complexes the size of small virus coats July 25th, 2016
Ultrasensitive sensor using N-doped graphene July 26th, 2016